INT245123

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.62
Pain Relevance 0.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CDKN2B) nucleus (CDKN2B) kinase activity (CDKN2B)
cytoplasm (CDKN2B)
CDKN2B (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 1 74.96 Quite High
antagonist 2 46.00 Quite Low
Bioavailability 18 5.00 Very Low Very Low Very Low
Potency 12 5.00 Very Low Very Low Very Low
adenocard 3 5.00 Very Low Very Low Very Low
anticonvulsant 3 5.00 Very Low Very Low Very Low
headache 3 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
sodium channel 1 5.00 Very Low Very Low Very Low
fibrosis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 236 99.26 Very High Very High Very High
Myeloid Leukemia 138 99.26 Very High Very High Very High
Lung Cancer 10 97.92 Very High Very High Very High
Myelodysplastic Syndromes 174 95.48 Very High Very High Very High
Carcinoma 33 94.56 High High
Metastasis 31 94.08 High High
Recurrence 11 89.60 High High
Acute Myeloid Leukemia 3 81.92 Quite High
Hemoptysis 1 78.96 Quite High
Pain 1 74.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Reexpression of p15 protein was increased and correlated with clinical response.
Gene_expression (Reexpression) of p15
1) Confidence 0.68 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 0.55 Pain Relevance 0
Surprisingly, patients with lower pretreatment levels of p15 methylation had a significantly higher response rate.
Gene_expression (methylation) of p15
2) Confidence 0.59 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 0.41 Pain Relevance 0
Higher levels of methylation in multiple genes (NOR1, NPM2,OLIG2, HINI, SLC26A4) were found in patients with good prognosis AML, while no significant difference in methylation of p15, CDH13 and PGR was found between good and poor prognosis groups [Kroeger et al.
Gene_expression (methylation) of p15 associated with myeloid leukemia
3) Confidence 0.59 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 1.00 Pain Relevance 0
The exception was an apparent increase in the overall 9p loss in rUC, which is the region containing the cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A and CDKN2B) genes.
Gene_expression (containing) of CDKN2B
4) Confidence 0.51 Published 2010 Journal BMC Med Genomics Section Body Doc Link PMC3022544 Disease Relevance 0.26 Pain Relevance 0
Expression of AR-regulated cell cycle genes, such as A-, B- and D-type cyclins, cyclin-dependent kinases (CDK1, CDK2, CDK4, CDK6) and cyclin-dependent kinase inhibitors (CDKN1B, CDKN2A, CDKN2B), was generally unaffected [40], [41], [42], [43], [44], [45].
Gene_expression (Expression) of CDKN2B
5) Confidence 0.38 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2957443 Disease Relevance 0 Pain Relevance 0
Loss of tumor suppressor gene RB, inactivation of CDK-inhibitor, and overexpression of epidermal growth-factor receptor might contribute to the development of neoplasm.
Gene_expression (overexpression) of CDK-inhibitor associated with cancer
6) Confidence 0.01 Published 2008 Journal Cases J Section Body Doc Link PMC2529260 Disease Relevance 1.40 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox